CN103930110A - 吡咯并喹啉基-吡咯烷-2,5-二酮制剂及制备和使用所述制剂的方法 - Google Patents

吡咯并喹啉基-吡咯烷-2,5-二酮制剂及制备和使用所述制剂的方法 Download PDF

Info

Publication number
CN103930110A
CN103930110A CN201280043415.6A CN201280043415A CN103930110A CN 103930110 A CN103930110 A CN 103930110A CN 201280043415 A CN201280043415 A CN 201280043415A CN 103930110 A CN103930110 A CN 103930110A
Authority
CN
China
Prior art keywords
composition
cancer
compound
cell
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280043415.6A
Other languages
English (en)
Chinese (zh)
Inventor
山小濑浩
加藤隆史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN103930110A publication Critical patent/CN103930110A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280043415.6A 2011-07-07 2012-07-06 吡咯并喹啉基-吡咯烷-2,5-二酮制剂及制备和使用所述制剂的方法 Pending CN103930110A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505175P 2011-07-07 2011-07-07
US61/505175 2011-07-07
PCT/US2012/045688 WO2013006761A2 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same

Publications (1)

Publication Number Publication Date
CN103930110A true CN103930110A (zh) 2014-07-16

Family

ID=47437711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280043415.6A Pending CN103930110A (zh) 2011-07-07 2012-07-06 吡咯并喹啉基-吡咯烷-2,5-二酮制剂及制备和使用所述制剂的方法

Country Status (14)

Country Link
US (2) US9180099B2 (https=)
EP (1) EP2729145A4 (https=)
JP (1) JP6073310B2 (https=)
KR (1) KR20140146036A (https=)
CN (1) CN103930110A (https=)
AU (1) AU2012278831A1 (https=)
BR (1) BR112013033807A2 (https=)
CA (1) CA2839584A1 (https=)
IN (1) IN2013MN02443A (https=)
MX (1) MX2014000253A (https=)
PH (2) PH12014500055A1 (https=)
TW (1) TW201315470A (https=)
WO (1) WO2013006761A2 (https=)
ZA (1) ZA201400108B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486872T1 (de) * 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
WO2013162714A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101474175A (zh) * 2009-01-20 2009-07-08 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
CN101636150A (zh) * 2007-04-06 2010-01-27 株式会社活效制药 微粉碎化有机化合物粒子的制造方法
US20110160242A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US8623405B2 (en) * 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
ATE486872T1 (de) 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
SI1897558T1 (sl) 2005-06-09 2014-03-31 Norgine Bv Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
BRPI1007972A2 (pt) 2009-02-12 2016-09-13 Arqule Inc composições de combinação e métodos para o tratamento de câncer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636150A (zh) * 2007-04-06 2010-01-27 株式会社活效制药 微粉碎化有机化合物粒子的制造方法
CN101474175A (zh) * 2009-01-20 2009-07-08 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
US20110160242A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
张汝华: "《工业药剂学》", 31 July 2001 *
李津明: "《现代制药技术》", 30 April 2005 *
肖全英: "国产麦迪霉素胶囊的溶出度研究", 《中国现代应用药学杂志》 *
袁卫: "粒度与制法对阿司匹林片溶出度的影响", 《海峡药学》 *
陈明: "干法制粒工艺在盐酸氢氯吡格雷片制备中的应用", 《中国药师》 *

Also Published As

Publication number Publication date
WO2013006761A2 (en) 2013-01-10
EP2729145A2 (en) 2014-05-14
BR112013033807A2 (pt) 2017-02-14
US20160022667A1 (en) 2016-01-28
PH12015501980A1 (en) 2017-10-18
JP6073310B2 (ja) 2017-02-01
ZA201400108B (en) 2016-03-30
PH12014500055A1 (en) 2016-02-08
IN2013MN02443A (https=) 2015-06-12
JP2014518284A (ja) 2014-07-28
WO2013006761A3 (en) 2013-04-18
TW201315470A (zh) 2013-04-16
AU2012278831A1 (en) 2014-01-16
US20130011481A1 (en) 2013-01-10
MX2014000253A (es) 2014-10-17
KR20140146036A (ko) 2014-12-24
US9180099B2 (en) 2015-11-10
CA2839584A1 (en) 2013-01-10
EP2729145A4 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
US9642847B2 (en) Combinational compositions and methods for treatment of cancer
EP2558085B1 (en) Compositions and methods for the prevention and treatment of cancer
TW202038951A (zh) 用於治療癌症之醫藥組合
US20190083521A1 (en) Combination therapy for treating cancer
US8575191B2 (en) Methods for treatment of non-small cell lung cancer
US8580764B2 (en) Combinational compositions and methods for treatment of cancer
JP6073310B2 (ja) ピロロキノリニル−ピロリジン−２，５−ジオン製剤及びその調製方法及び使用方法
US20110301194A1 (en) Method for Determining Treatment Efficacy
TW201215610A (en) Combinational compositions and methods for treatment of cancer
HK1181312A (en) Compositions and methods for the prevention and treatment of cancer
HK1181312B (en) Compositions and methods for the prevention and treatment of cancer
HK1164159B (en) A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140716

WD01 Invention patent application deemed withdrawn after publication